Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof
US11541126B1 · kind B1 · utility
0Cited by
31References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2021 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Jul 1, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.